GRAFT POLYMER UK LS -001 (J4I) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has a cash flow conversion efficiency ratio of -0.048x as of November 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-149.00K ≈ $-174.20K USD) by net assets (€3.08 Million ≈ $3.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See J4I equity to assets ratio to measure how much of total assets are equity-financed.
GRAFT POLYMER UK LS -001 - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how GRAFT POLYMER UK LS -001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore GRAFT POLYMER UK LS -001 (J4I) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
GRAFT POLYMER UK LS -001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Malaysian Genomics Resource
KLSE:0155
|
0.005x |
|
Vyome Holdings, Inc.
NASDAQ:HIND
|
1.108x |
|
Kalo Gold Corp
NASDAQ:KLGDD
|
-2.311x |
|
HF Company SA
PA:ALHF
|
0.038x |
|
TryHard Holdings Limited Ordinary Shares
NASDAQ:THH
|
0.000x |
|
TALKPOOL AG SF-05
F:TKPL
|
-0.130x |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
-0.026x |
|
Esthetics International Group
KLSE:5081
|
0.079x |
Annual Cash Flow Conversion Efficiency for GRAFT POLYMER UK LS -001 (2023–2025)
The table below shows the annual cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of GRAFT POLYMER UK LS -001.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | €3.08 Million ≈ $3.61 Million |
€-1.13 Million ≈ $-1.32 Million |
-0.366x | +40.04% |
| 2024-05-31 | €2.03 Million ≈ $2.37 Million |
€-1.24 Million ≈ $-1.45 Million |
-0.611x | -17.91% |
| 2023-05-31 | €4.55 Million ≈ $5.32 Million |
€-2.36 Million ≈ $-2.76 Million |
-0.518x | -- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more